evipedia.ai
← Back

sh-Oligopeptide-1 for Hair Regrowth

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: rh-Oligopeptide-1, sh-EGF, Synthetic Human Epidermal Growth Factor, Recombinant Human Epidermal Growth Factor, rhEGF, Epidermal Growth Factor, EGF, Nepidermin, Urogastrone

Motivation

sh-Oligopeptide-1 is the cosmetic ingredient name for a lab-made copy of human epidermal growth factor, a small signaling protein that tells skin and hair-follicle cells to grow, move and repair. It is sold in scalp serums, microneedling solutions and in-clinic scalp injection mixtures aimed at people who want thicker hair, either instead of or alongside conventional hair-loss medicines.

Interest comes from two directions. The same growth factor is already used as a medicine for stubborn wounds, and laboratory work has examined how hair follicles respond to it and whether it helps set the timing of the growth cycle. Cancer medicines that block its action were also noticed to change how hair grows, which drew attention to this signal as a possible lever for hair.

This review examines whether applying sh-Oligopeptide-1 to the scalp, alone or within multi-ingredient products, regrows hair in adults with thinning hair. It sets out the human, animal and laboratory evidence, the risks, including open questions about product quality and long-term safety, and how the ingredient is used in practice.

Benefits - Risks - Protocol - Conclusion

Selected expert commentary and primary research on epidermal growth factor (EGF, the signaling protein that sh-Oligopeptide-1 copies) its role in the hair follicle, and growth-factor hair treatments.

Only four items are listed because no further eligible source discusses EGF, sh-Oligopeptide-1 or growth-factor hair treatments in depth. No such content was found from Rhonda Patrick, Chris Kresser or Lifespan.io: their hair-related content covers other topics (sulforaphane, laser therapy and graying; nutrition and alopecia areata (autoimmune patchy hair loss); general aging research) rather than growth factors. Andrew Huberman’s hair episode mentions platelet-rich plasma only briefly, as a blood-flow tool, without discussing growth factors.

Grokipedia

Epidermal growth factor

Broad overview of EGF biology, history and clinical uses; notes sh-Oligopeptide-1 as its cosmetic form and summarizes mixed hair-cycle findings, including mouse data after chemotherapy-induced hair loss.

Examine

Epidermal Growth Factor (EGF)

Examine’s dedicated EGF page treats it as a measured outcome of supplements, not as a topical treatment; it lists one small trial and contains no hair-regrowth data.

ConsumerLab

No ConsumerLab article on sh-Oligopeptide-1 or epidermal growth factor exists.

Systematic Reviews

The following systematic reviews and meta-analyses cover sh-Oligopeptide-1 or recombinant EGF, growth-factor scalp treatments for androgenetic alopecia (hereditary pattern hair loss) including mesotherapy (series of shallow scalp injections), and the safety of EGF and injection-based delivery.

Mechanism of Action

sh-Oligopeptide-1 is recombinant human EGF, a 53-amino-acid signaling protein made in bacteria. EGF binds the EGF receptor (EGFR, a cell-surface enzyme that switches on growth signals), which pairs with the related receptor ErbB2 (also called HER2). In the hair follicle these receptors sit mainly in the outer root sheath (the outer sleeve of cells around the growing hair). Binding triggers the MAPK/ERK and PI3K/Akt cascades (relay pathways that drive cell division and survival). In cultured follicle cells, EGF at 2–20 ng/mL, but not at higher or lower concentrations, increased outer root sheath growth and migration through Wnt/β-catenin signaling (the main pathway that keeps follicles in the growth phase) (Zhang et al., 2016).

A competing explanation holds that EGF is an on-off switch rather than a growth accelerator. Receptor signaling is needed to start anagen (the growth phase), yet continuous EGF in genetically engineered mice arrested follicle development (Mak & Chan, 2003), and isolated human follicles exposed to EGF stopped making fiber and adopted a catagen-like (regression-phase) shape (Philpott & Kealey, 1994). The net effect therefore depends on dose, timing and hair-cycle phase.

Pharmacology: a 6.2 kDa protein held together by three disulfide bonds. It penetrates intact stratum corneum (the skin’s outer barrier) poorly and enters mainly through follicle openings or channels made by microneedling (Miller-Kobisher et al., 2021). It is selective for EGFR, is cleared from blood within minutes by receptor uptake in liver and kidney, and is degraded by protein-cutting enzymes, not cytochrome P450 enzymes (drug-clearing liver enzymes).

Historical Context & Evolution

EGF was discovered in 1962 by Stanley Cohen (Cohen, 1962), who found that an extract of mouse salivary glands made newborn mice open their eyelids and erupt teeth early; the work earned a share of the 1986 Nobel Prize. The human form was purified from urine as urogastrone, a stomach-acid suppressor, and later shown to be the same molecule.

The first hair findings pointed toward inhibition. Newborn mice injected with EGF grew slower, thinner hair (Moore et al., 1981), and Australian researchers found that infusing EGF into Merino sheep made fleeces break and shed, explored as “biological wool harvesting” (Moore et al., 1982). These studies used high systemic doses, not topical scalp application.

Recombinant production made the protein inexpensive. South Korea approved topical recombinant EGF for diabetic foot ulcers in 2001, and the cosmetics industry adopted it under the ingredient name sh-Oligopeptide-1, first for facial skin and later for scalp serums and microneedling or injection mixtures. It was never developed or approved as a hair-loss drug.

Opinion shifted as laboratory work showed that EGF can support follicle cells at low concentrations and acts as a timing switch within the hair cycle (Mak & Chan, 2003). A 2023 critique countered that cosmetic-grade sh-Oligopeptide-1 has never been shown to be biologically active and that favorable product trials do not follow medical standards (Martínez-Carpio, 2023). Neither the growth-promoting nor the growth-braking view has been tested head-to-head on human scalps, so the question remains open.

Expected Benefits

High 🟩 🟩 🟩

Faster healing of chronic skin wounds and burns ⭕️ Not Central to Hair Regrowth

Recombinant EGF speeds closure of chronic wounds and burns by driving skin-cell growth and migration. A meta-analysis of nine randomized controlled trials in diabetic foot ulcers found higher complete healing and shorter healing time (Zhao et al., 2020), confirmed by a second meta-analysis (Bui et al., 2019); a meta-analysis of randomized burn trials found faster healing of partial-thickness burns (Zhang et al., 2016). These trials used pharmaceutical-grade EGF, not cosmetic sh-Oligopeptide-1. This bears on skin repair, including scalp recovery after microneedling, not hair regrowth.

Magnitude: Odds ratio (how many times higher the odds of healing were) 2.79 for complete healing of foot ulcers (95% confidence interval, the range of plausible values, 1.99–3.99) and healing 14.1 days faster, across 720 participants; partial-thickness burns healed 3.12 days faster with EGF (95% confidence interval 1.11–5.13).

Better acne-scar repair after laser treatment ⭕️ Not Central to Hair Regrowth

Recombinant EGF applied after fractional carbon dioxide laser supports skin repair and improves the appearance of sunken acne scars. A meta-analysis of 12 randomized trials, all from China, found lower scar-severity scores and less darkening of the skin than with laser alone (Zhou et al., 2026), consistent with a split-face trial in 23 patients (Ratanapokasatit & Sirithanabadeekul, 2022). Certainty was rated very low to moderate. This bears on facial skin, not on scalp hair.

Magnitude: Acne-scar severity scores fell by a mean of 11.14 points more than with laser alone (95% confidence interval 5.45–16.82) across 12 randomized trials with 1,044 patients.

Medium 🟩 🟩

Fewer acne lesions ⭕️ Not Central to Hair Regrowth

In a randomized, placebo-controlled split-face trial in 20 Korean adults, recombinant EGF cream applied twice daily for six weeks reduced acne lesions and oil output (Kim et al., 2014). The trial was small and single-center. This bears on facial skin quality, not on scalp hair.

Magnitude: Inflammatory acne lesions fell 33.5% and non-inflammatory lesions 25.4% on the EGF side after six weeks, while lesions increased on the placebo side.

Reduced facial wrinkles ⭕️ Not Central to Hair Regrowth

Facial anti-wrinkle products are the ingredient’s main cosmetic use. In a randomized, double-blind split-face trial in 50 Korean women, an EGF-carrying microneedle patch reduced deep eye-area wrinkles more than the patch alone (An et al., 2019), but photodamage scores did not differ. The evidence rests on this single trial. This bears on facial skin, not hair.

Magnitude: Deep wrinkles around the eyes improved 12.9% with the EGF patch versus 3.5% with the patch alone at day 5; photodamage scores fell 7.4% versus 5.8%, not significantly different.

Lighter melasma patches ⭕️ Not Central to Hair Regrowth

Melasma (symmetric brown patches on the face) was treated with a topical EGF serum applied twice daily for eight weeks. In a randomized, double-blind, placebo-controlled split-face trial in 15 women, the EGF side improved more than the placebo side, with no adverse events (Lyons et al., 2018). The trial was small and short. This bears on facial pigmentation, not on scalp hair.

Magnitude: Physician-rated melasma improved in 73.4% of subjects on the EGF side versus 13% on the placebo side after eight weeks.

Fewer skin reactions to cancer treatment ⭕️ Not Central to Hair Regrowth

Recombinant EGF applied to the skin was tested against skin damage caused by cancer therapy. In a double-blind, placebo-controlled trial in 80 patients with rash from EGFR-blocking cancer drugs, EGF ointment improved lesions and skin-related quality of life, more so at the higher strength (Kim et al., 2020). A randomized trial in 40 patients receiving breast radiotherapy found less severe radiation dermatitis (radiation-induced skin inflammation) with an EGF cream (Kong & Hong, 2013). Each use rests on one small trial. This bears on skin during cancer treatment, not hair.

Magnitude: 77.8% of patients responded to the 20 ppm (parts per million) EGF ointment versus 44.4% with placebo; severe radiation dermatitis occurred in 15% versus 40% of patients, a difference significant only in the adjusted analysis.

Faster healing of the eye surface ⭕️ Not Central to Hair Regrowth

EGF eye drops, ointments or contact lenses have been tested for corneal (clear front of the eye) wounds, dry eye and nonhealing ulcers. A randomized, double-blind, placebo-controlled multicenter trial in 104 patients with traumatic corneal defects found faster surface healing with EGF eye drops (Pastor & Calonge, 1992). A systematic review of 10 clinical and 38 experimental studies judged the human evidence promising but scarce (Sanie-Jahromi et al., 2025). This bears on the eye, not hair.

Magnitude: Mean healing time was 44.2 hours with EGF eye drops versus 61.1 hours with placebo in the 104-patient trial of traumatic corneal defects.

Low 🟩

Increased hair density and thickness in thinning hair ⚠️ Conflicted

Human data come from multi-ingredient protocols: an uncontrolled 10-patient series of microneedling, light and an sh-Oligopeptide-1 solution (Gentile, 2022) and a retrospective study of EGF-containing injections (Stefanis et al., 2024). Laboratory data conflict: EGF stimulated sheath cells (Zhang et al., 2016) but can halt growth. Net: EGF-driven regrowth is unproven.

Magnitude: Hair density rose from 47 to 58 hairs/cm² after 20 weeks in the uncontrolled series (not statistically significant versus baseline); the EGF-containing injection group improved only crown (vertex) measures after six months.

Less severe oral mucositis during cancer treatment ⭕️ Not Central to Hair Regrowth ⚠️ Conflicted

Oral mucositis (painful mouth sores from cancer therapy) was tested with recombinant EGF spray in two placebo-controlled trials. Severe mucositis fell during head and neck radiotherapy (Wu et al., 2009) but not after intensive chemotherapy (Kim et al., 2017). This bears on the mouth, not hair. Net: benefit is unconfirmed.

Magnitude: With the 50 µg/mL spray, 64% versus 37% of radiotherapy patients avoided severe mucositis; the chemotherapy trial found no difference in grade 2 or higher mucositis.

Speculative 🟨

Protection from chemotherapy-induced hair loss

In mice, topical EGF in liposomes (fat-based carriers) before cyclophosphamide (a chemotherapy drug) protected follicles and aided recovery (Paik et al., 2013). No human data exist; the basis is animal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in the EGF and EGFR genes have been linked to alopecia areata (autoimmune patchy hair loss) susceptibility in a Korean cohort (Won et al., 2019); no study links any variant to response to topical EGF.
  • Baseline biomarkers: Low ferritin (iron stores), thyroid dysfunction or vitamin D deficiency cause shedding that a growth factor cannot offset; correcting these first makes any added effect easier to judge.
  • Sex: Published hair data pool men with androgenetic alopecia (hereditary pattern hair loss) and women with female pattern hair loss; one series reported higher satisfaction in men (Gentile, 2022), but no study compares response by sex.
  • Type of hair loss: Follicles that are miniaturized but still present, as in early pattern loss or telogen effluvium (diffuse shedding after a stressor), are the plausible responders; scarred or long-bald areas lack follicles to act on.
  • Age: Older adults have fewer active follicles and slower skin repair. In the one injection study, the EGF-product group was youngest and the oldest group used a product without EGF, so EGF response by age is unknown (Stefanis et al., 2024).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event attributable to topical or injected EGF has been shown in more than one controlled trial.

Medium 🟥 🟥

No risk reaches Medium: scalp-specific harm data come from uncontrolled case series and reviews of case reports, not from any controlled trial showing excess harm.

Low 🟥

Mild local skin reactions

Itching, mild redness and transient numbness were tracked as expected effects in a microneedling case series using an sh-Oligopeptide-1 solution, which reported no event counts (Gentile, 2022). In randomized wound trials, adverse events with recombinant EGF did not differ from placebo (Zhao et al., 2020). Reactions are mild and reversible.

Magnitude: Across 9 randomized trials (720 participants), adverse-event rates showed no significant difference from placebo; the scalp case series did not report rates.

Complications of scalp injection or microneedling

Growth-factor mixtures are often delivered by mesotherapy (series of shallow scalp injections). Reviews of injectable hair treatments report paradoxical hair loss, scarring and acute dermatitis (Beer et al., 2026; Gupta et al., 2023). These harms stem from the procedure and product mix, not EGF specifically.

Magnitude: Not quantified in available studies. The reviews compile case reports and small series without denominators, so no rate can be calculated.

Unwanted hair growth outside the treated area

A published case letter raised the possibility of unwanted local hair growth at a wound treated with topical EGF (Hyun et al., 2016). Causality is uncertain; the relevance to scalp users is run-off onto the forehead or face.

Magnitude: Not quantified in available studies. Only a single case letter exists.

Worsening of alopecia areata

Blood EGF levels were higher with more severe alopecia areata in a case-control study of 60 patients (El-Refai et al., 2020). This is an indirect association in people; no study tested whether applied EGF worsens the condition.

Magnitude: Not quantified in available studies. The only study compared blood EGF with disease severity and did not measure flares after applied EGF.

Speculative 🟨

Paradoxical shedding from a forced hair-cycle shift

EGF pushed isolated human follicles into a regression-like state (Philpott & Kealey, 1994) and caused fleece shedding in sheep (Moore et al., 1982). No human scalp data exist; the basis is laboratory and animal only.

Promotion of existing skin or other tumors

EGF receptor signaling drives growth of several cancers. No human reports link topical EGF to cancer, but long-term risks of cosmetic use are unstudied (Martínez-Carpio, 2023); basis is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic variant is known to change the risk of reactions to topical EGF; EGF and EGFR variants linked to alopecia areata susceptibility raise an untested question for people with that condition.
  • Baseline biomarkers: Platelet count below 50,000/µL or an INR (clotting-time measure) above the therapeutic range raises bleeding and bruising risk with injection or microneedling delivery.
  • Sex: No sex difference in reactions is reported. Pregnancy and breastfeeding lack any safety data for scalp growth-factor products.
  • Pre-existing conditions: A history of skin cancer on the scalp, active scalp infection, eczema or psoriasis, alopecia areata, and keloid (raised overgrown scar) tendency raise the risk or consequence of adverse effects.
  • Age: Older adults have thinner, more sun-damaged scalp skin, more precancerous lesions on bald areas, and slower healing after microneedling or injections.

Key Interactions & Contraindications

  • EGFR-targeted cancer drugs (erlotinib, gefitinib, osimertinib, cetuximab, panitumumab): Severity: avoid unless the treating oncologist agrees. Opposing action on the same receptor; topical EGF may be ineffective, and its effect on tumor control is unknown.
  • Topical retinoids (vitamin A-derived skin medicines; tretinoin, adapalene): Severity: caution. Increased skin penetration and irritation; mitigation: alternate-evening use or several hours’ separation, with watch for redness or peeling.
  • Anticoagulants and antiplatelet drugs (blood thinners; warfarin, apixaban, clopidogrel, aspirin): Severity: caution with injection or microneedling delivery. More bruising and pinpoint bleeding; mitigation: shallower needles (0.25 mm) or topical-only application.
  • Potent topical corticosteroids (anti-inflammatory steroid creams; clobetasol, betamethasone): Severity: monitor. Slower skin repair and possible blunting of EGF-driven cell growth; mitigation: separate application sites or times.
  • Topical minoxidil (over-the-counter): Severity: monitor. Often combined; no known chemical interaction, but stacking liquids raises scalp irritation; mitigation: application at different times of day.
  • Ketoconazole shampoo (over-the-counter): Severity: no known interaction. Serum applied after the shampoo is rinsed out avoids dilution.
  • Supplements: No supplement is known to alter EGF uptake. Additive-effect products: copper peptide GHK-Cu and sh-Polypeptides mimicking FGF (fibroblast growth factor) or IGF-1 (insulin-like growth factor 1). Severity: monitor; possible added scalp irritation and untested combined growth stimulation; mitigation: one new product at a time.
  • Microneedling, fractional laser and light therapy: Severity: monitor; potentiating. They raise EGF penetration and also infection and irritation risk; mitigation: sterile products only, and a 24-hour wait before non-sterile serums touch fresh channels.

Populations who should avoid Sh-Oligopeptide-1:

  • Active scalp skin cancer, or skin cancer on the scalp treated within the past 5 years
  • Current treatment with EGFR-targeted cancer drugs, unless approved by the treating oncologist
  • Pregnancy and breastfeeding (no safety data)
  • Active scalp infection, open wounds or flaring scalp dermatitis
  • Known hypersensitivity to EGF products or their preservatives
  • For injection or microneedling only: platelet count below 50,000/µL, INR above the therapeutic target, or history of keloids

Risk Mitigation Strategies

  • Patch test before scalp use: Daily application to a 2 cm area behind the ear for 3–5 days detects irritation or allergy before full-scalp exposure.
  • Shallow, sterile needling: Home protocols using 0.25–0.5 mm needles, sterile single-use heads and at most two sessions weekly limit infection, scarring and bruising.
  • Clinic-only injections: Mesotherapy performed by licensed clinicians with sterile, labeled vials reduces infection, scarring and paradoxical hair loss from contaminated or unknown mixtures.
  • Contained application: Dropper application along partings, away from the hairline edge, followed by hand washing prevents unwanted hair growth on the forehead or face.
  • Photo and shedding baseline: Standardized photos and a pull test before starting and at 8–12 weeks detect early paradoxical shedding, prompting the product to be stopped.
  • Annual scalp skin check: A yearly dermatologist examination of the scalp, or sooner for new or changing spots, addresses the theoretical tumor-promotion risk.

Therapeutic Protocol

  • At-home topical approach: A serum listing sh-Oligopeptide-1, applied at 1–2 mL to the thinning areas once daily on a dry scalp, used for at least 16–24 weeks; this is the typical cosmetic regimen, without a standardized dose.
  • Device-assisted microneedling approach: Microneedling stamp plus red and blue light with a growth-factor solution twice weekly for 20 weeks (40 sessions), as described by plastic surgeon Pietro Gentile of Tor Vergata University, Rome (Gentile, 2022).
  • In-clinic mesotherapy approach: Intradermal injections spaced 0.5–1 cm apart with a 4 mm needle, every 2 weeks for 6 sessions, as used at a Prague university dermatology department (Stefanis et al., 2024).
  • Choosing among approaches: Topical use relies on follicle entry; needling and injections bypass the skin barrier but add procedure risks. Some users add EGF to minoxidil or finasteride, others use it alone; neither pattern has been compared in trials.
  • Concentration: Manufacturers rarely disclose EGF content; the Prague report (Stefanis et al., 2024) listed no EGF concentration. Laboratory data suggest a narrow effective window, so higher-strength claims are not evidence of greater effect.
  • Time of day: Evening application after washing and drying the hair, left on overnight, maximizes contact time and avoids wash-out by sweat or styling products.
  • Half-life: EGF is cleared from blood within minutes and degraded by skin enzymes; how long it stays active in the scalp is unknown, which is why daily application is used.
  • Single or split dose: Once daily is standard for scalp serums; facial trials used twice daily (Kim et al., 2014). No study shows that splitting the dose improves hair outcomes.
  • Genetic polymorphisms: No gene variant is known to change EGF dosing; routine genetic testing is not used for this ingredient.
  • Sex: No sex-specific dosing exists. Women with female pattern hair loss and men with pattern hair loss use the same regimens; pregnancy is an exclusion.
  • Age: For adults over 60 or with thin scalp skin, shorter needles (0.25 mm) and less frequent needling reduce trauma while keeping delivery.
  • Baseline biomarkers: Checking and correcting ferritin, thyroid function and vitamin D before starting helps separate a growth-factor effect from recovery of a nutrient or hormone deficit.
  • Pre-existing conditions: Pattern hair loss and post-illness shedding are the studied uses; alopecia areata and scarring hair loss are usually managed with dermatologist-directed treatment first.

Discontinuation & Cycling

  • Duration: Treated as a trial of 4–6 months; if hair density on standardized photos has not improved, continued use has no supporting evidence. Responders who continue do so indefinitely, as with other hair treatments.
  • Withdrawal effects: No withdrawal effects are reported. Any gains are expected to fade gradually after stopping, as with other topical hair treatments, though this has not been measured.
  • Tapering: No tapering is needed; the ingredient can be stopped at once. Microneedling frequency can be reduced gradually if both are stopped together.
  • Cycling: No evidence supports cycling. The laboratory “on-off switch” model raises the idea of intermittent use, but no human study has tested it.

Sourcing and Quality

  • Form and bioactivity: sh-Oligopeptide-1 (bacteria-made) and rh-Oligopeptide-1 are both sold as EGF; cosmetic grades are not required to prove biological activity, a central criticism of the category (Martínez-Carpio, 2023).
  • What to look for: Ingredient listed high on the INCI (International Nomenclature of Cosmetic Ingredients) list, disclosed concentration, a certificate of analysis or third-party activity test, airless or opaque packaging, and refrigeration guidance.
  • Stability: EGF is a fragile protein; heat, light and repeated opening degrade it. Products stored cool and used within the stated period-after-opening are more likely to retain activity.
  • Products used in studies: HR3 Matrix Hair Solution (DTS MG, Korea) in the microneedling series (Gentile, 2022) and allstem. (Scimed Pharma) in the Prague injection study (Stefanis et al., 2024); plant-grown EGF is sold by Bioeffect (Iceland) for skin.
  • Injection products: Sterile, batch-labeled vials from licensed suppliers, handled by a clinician, are the quality benchmark; unlabeled “growth factor cocktails” from online sellers carry unknown content and contamination risk.

Practical Considerations

  • Time to effect: Human studies assessed hair at 20 weeks to 6 months (Gentile, 2022; Stefanis et al., 2024); visible density change, if any, would be expected after 3–6 months because hair grows about 1 cm per month.
  • Common pitfalls: Starting without a diagnosis of the hair-loss type, skipping baseline photos, inconsistent application, stopping proven treatments in favor of an unproven serum, and judging results before 4 months.
  • Regulatory status: Sold as a cosmetic ingredient in the US, EU and Asia without efficacy review. Recombinant EGF is an approved drug for wound healing in some countries, but not for hair loss anywhere.
  • Cost and accessibility: Serums are widely available at moderate cost; in-clinic mesotherapy series are expensive. Insurers treat hair loss as cosmetic, so no payer has a financial incentive favoring EGF products over generic medicines.

Interaction with Foundational Habits

  • Sleep: No direct interaction; EGF does not affect sleep. Indirectly, chronic short sleep raises stress hormones linked to shedding, and evening application aligns with overnight scalp contact time.
  • Nutrition: No direct interaction. Follicles need adequate protein, iron, zinc and vitamin D to build hair; a growth-factor signal cannot compensate for deficiencies, so a nutrient-replete diet is the base on which any EGF effect would act.
  • Exercise: No blunting effect known. Heavy sweating dilutes and washes off topical serums, so applying after the post-exercise shower preserves contact time; no effect on muscle growth is expected from scalp application.
  • Stress management: Indirect. Stress triggers telogen effluvium (diffuse shedding), which can mask or mimic treatment response; EGF has no known effect on cortisol, so stress reduction is a separate lever.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes the type of hair loss and removes common reversible causes. It includes standardized photographs of the crown, part line and hairline under fixed lighting, trichoscopy (magnified scalp imaging) of marked sites for hair density and shaft diameter, a hair pull test, a scalp skin examination, and blood tests for ferritin, thyroid function, vitamin D and zinc.

Ongoing monitoring follows a fixed cadence: photographs and a pull test at 8–12 weeks to catch early shedding, then trichoscopy and photographs every 3 months for the first year. Blood tests are repeated at 3–6 months only if a deficiency was corrected. A scalp skin examination is repeated every 12 months. Success is defined as a measurable rise in density or diameter at the marked sites by 6 months, confirmed by photographs.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–150 ng/mL Iron stores support hair growth Conventional range about 15–150 ng/mL (women) and 30–400 ng/mL (men); no fasting needed; pair with CBC (complete blood count)
TSH 0.5–2.5 mIU/L Thyroid imbalance causes shedding TSH (thyroid-stimulating hormone); conventional range 0.4–4.5 mIU/L; morning draw; pair with free T4 (free thyroxine)
25-hydroxyvitamin D 40–60 ng/mL Deficiency linked to hair loss Conventional range 30–100 ng/mL; retest 3 months after correction
Zinc (serum) 90–120 µg/dL Deficiency causes shedding Conventional range about 60–120 µg/dL; morning fasting draw preferred
Hair density (trichoscopy) No established target; track change from own baseline at marked sites Primary regrowth measure Same device, magnification and marked crown and frontal sites each time; every 3 months
Hair shaft diameter No established target; track change from own baseline Thickening often precedes visible density Measured with density at the same sites; report mean diameter in µm
Hair pull test 2 or fewer hairs from about 60 pulled Gauges active shedding No hair washing for 24 hours beforehand; more than 6 hairs indicates active shedding
Scalp skin examination No new or changing lesions Screens for tumors under growth-factor exposure Dermatologist examination yearly; bald scalp is highly sun-exposed

Qualitative markers:

  • Visible fullness of the part line and crown in standardized photographs
  • Amount of hair on the pillow, in the shower drain and on the brush
  • Scalp comfort: itching, redness, flaking or tenderness after application
  • Perceived hair thickness and styling volume
  • Satisfaction with appearance, rated on a simple 0–10 scale at each photo check

Emerging Research

  • No dedicated hair trial of sh-Oligopeptide-1: Registry searches found no trial testing the ingredient alone. The closest registered study, NCT05129800, is a completed retrospective comparison of PRP (platelet-rich plasma) and mesotherapy in 72 patients, one arm using an EGF-containing product.
  • Peptide serum versus minoxidil: NCT07536100 is a recruiting, triple-blind randomized trial (80 participants, 24 weeks) comparing a peptide-factor hair serum with 2% minoxidil for pattern hair loss; the registry does not disclose whether the serum contains EGF, limiting direct relevance.
  • Engineered EGF delivery: Exosomes (tiny cell-derived carriers) loaded with EGF and FGF restored hair in androgen-treated mice, and EGF was reduced in dermal papilla cells (the signaling hub at the follicle base) from human balding scalp (Lai et al., 2026), which could strengthen the case if translated to people.
  • EGF receptor as a brake: Mouse work shows EGFR restrains Wnt/β-catenin signaling and that its loss disrupts follicle development (Tripurani et al., 2018), supporting the view that more receptor stimulation is not simply better and could weaken the case.
  • Bioactivity verification: Independent assays confirming that cosmetic sh-Oligopeptide-1 activates the receptor at labeled concentrations are lacking; such testing could decide whether existing product trials measure the ingredient at all (Martínez-Carpio, 2023).
  • Combination signaling: EGF alone did not rescue androgen-suppressed hair in mice, but did with Jagged1 (a follicle-signaling protein) (Lin et al., 2019), pointing research toward defined growth-factor combinations rather than single-ingredient serums.

Conclusion

sh-Oligopeptide-1 is a lab-made copy of human epidermal growth factor sold in scalp serums, needling solutions and injection mixtures for thinning hair. For health-focused adults willing to invest effort in their hair, the central finding is that its benefit for regrowth rests on thin ground. The only human hair data come from small studies without comparison groups, or from looks back at clinic records, all testing products that mix this ingredient with several others, often delivered with needling or light devices, so its own contribution cannot be separated out. Laboratory and animal work points both ways: the growth factor can support follicle cells at low levels, yet high or constant exposure can stop hair production. The same molecule has strong evidence for healing chronic wounds and burns and repairing acne scars after laser treatment, and some evidence for other skin uses, including easing skin reactions during cancer treatment, but those uses do not bear directly on hair.

Harms reported so far are mild and mostly tied to the delivery method, such as scalp irritation, bruising or rare scarring from injections. Long-term safety of repeated growth-factor exposure is unstudied. A further uncertainty is product quality: cosmetic-grade material has not been shown to be biologically active, sellers are not required to prove any effect, and published product studies have been criticized for falling short of medical research standards. The evidence on this ingredient for hair regrowth is best described as unresolved rather than supportive or disproven.

Top - Benefits - Risks - Protocol